Vascular Malformation Pipeline Summary

DelveInsight’s, “Vascular Malformation - Pipeline Insight, 2026” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Vascular Malformation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Vascular Malformation: Understanding

Vascular Malformation: Overview

Vascular malformations are congenital abnormalities of blood-vessel development that arise from defects in the formation, structure, or function of vascular channels. They may involve capillaries, veins, arteries, lymphatic vessels, or combinations of these, while the malformed vessels retain a normal endothelial lining. Their clinical presentation is highly variable, ranging from asymptomatic or cosmetic lesions to pain, swelling, bleeding, functional impairment, and potentially life-threatening complications. They are broadly classified into capillary, venous, arteriovenous, and lymphatic malformations, with further classification based on flow characteristics and associated syndromes.

Vascular malformations primarily result from abnormal vascular development during fetal life, although their clinical manifestations may become apparent later. Increasing evidence indicates that genetic abnormalities, particularly somatic mutations acquired during development, play an important role. Most sporadic lesions arise from activating mutations affecting vascular signaling pathways, while a smaller proportion are associated with inherited genetic alterations. Mutations involving pathways such as PI3K/AKT/mTOR and RAS/RAF/MEK/ERK can disrupt normal vascular growth, differentiation, and remodeling. Certain inherited disorders, such as hereditary hemorrhagic telangiectasia (HHT), can also predispose individuals to specific vascular malformations.

The pathophysiology involves abnormal endothelial signaling, vascular remodeling, and vessel maturation, resulting in malformed, dilated, or abnormally connected vascular channels. Dysregulated PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signaling promotes abnormal cell growth, proliferation, angiogenesis, and vascular development. For example, venous malformations are frequently associated with activating TEK/TIE2 or PIK3CA mutations, which lead to abnormal venous-channel formation and function. Depending on the affected vessel type, lesions may exhibit slow flow, as seen in venous and lymphatic malformations, or high flow, as seen in arteriovenous malformations. Chronic blood stasis in venous lesions can further result in thrombosis, pain, and phlebolith formation.

Diagnosis is based on clinical examination combined with appropriate imaging, with the choice depending on the suspected type and extent of the malformation. Superficial lesions can often be identified clinically, while Doppler/duplex ultrasonography is useful for assessing blood flow and distinguishing slow- from fast-flow lesions. MRI is particularly important for defining the depth and anatomical extent of lesions and their relationship with surrounding muscles, bones, and organs. CT may be useful for selected lesions, while angiography provides detailed vascular anatomy and is particularly valuable for arteriovenous malformations and treatment planning. Laboratory investigations, such as D-dimer, may support the diagnosis of venous malformations with localized intravascular coagulation, whereas histopathology is reserved for selected cases.

Management is individualized according to the type, size, location, extent, symptoms, and complications of the malformation. Observation may be appropriate for asymptomatic lesions, while symptomatic or functionally significant lesions may require intervention. Surgical excision can be used for selected localized lesions, whereas sclerotherapy and embolization are important minimally invasive approaches for venous and arteriovenous malformations. For complex lesions, multidisciplinary management involving dermatology, interventional radiology, surgery, and other specialists may be required. Increasing understanding of the molecular basis of vascular malformations has also introduced targeted therapies such as sirolimus, particularly for complex or treatment-resistant lesions, although their use depends on the specific malformation and clinical setting.

"Vascular Malformation- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Malformation pipeline landscape is provided which includes the disease overview and Vascular Malformation treatment guidelines. The assessment part of the report embraces, in depth Vascular Malformation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Malformation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Malformation R&D. The therapies under development are focused on novel approaches to treat/improve Vascular Malformation.

Vascular Malformation Emerging Drugs Chapters

This segment of the Vascular Malformation report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vascular Malformation Emerging Drugs

Engasertib: Vaderis Therapeutics / ALMAC

Engasertib (VAD044), developed by Vaderis Therapeutics, is an investigational oral, selective allosteric AKT inhibitor being developed for Hereditary Hemorrhagic Telangiectasia (HHT). By modulating the AKT signaling pathway involved in abnormal blood-vessel formation, engasertib is intended to reduce the recurrent bleeding associated with HHT, particularly epistaxis (nosebleeds). A Phase II proof-of-concept study demonstrated reductions in epistaxis frequency and duration, with a generally manageable safety profile. The program has advanced to Phase III, evaluating engasertib in adults with moderate-to-severe HHT, with epistaxis frequency as the primary efficacy endpoint.

ALN-6400: Alnylam Pharmaceuticals

ALN-6400 (not ALN-640) is an investigational GalNAc-conjugated RNA interference (RNAi) therapeutic developed by Alnylam Pharmaceuticals for Hereditary Hemorrhagic Telangiectasia (HHT). It targets plasminogen (PLG) to reduce circulating plasminogen and potentially improve hemostasis, thereby addressing the recurrent bleeding associated with HHT. Preclinical studies showed substantial PLG reduction without evidence of increased thrombosis risk, and the program entered Phase II clinical development in HHT in late 2025.

TER-4480: Terremoto

TER-4480 is an investigational, orally bioavailable, selective AKT1 inhibitor being developed specifically for Hereditary Hemorrhagic Telangiectasia (HHT). By selectively targeting AKT1, which is implicated in HHT pathogenesis, it is designed to minimize the toxicity associated with pan-AKT inhibition and support long-term use. In preclinical models, TER-4480 completely prevented the development of arteriovenous malformations (AVMs). The program is currently in preclinical studies, with clinical trials expected to begin in 2026.

Further product details are provided in the report……..

Vascular Malformation: Therapeutic Assessment

This segment of the report provides insights about the different Vascular Malformation drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Vascular Malformation
• There are approx. 15+ key companies which are developing the therapies for Vascular Malformation. The companies which have their Vascular Malformation drug candidates in the most advanced stage, i.e. Phase III include, Vaderis Therapeutics.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Vascular Malformation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vascular Malformation: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Vascular Malformation therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Malformation drugs.

Vascular Malformation Report Insights

• Vascular Malformation Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vascular Malformation Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Vascular Malformation drugs?
• How many Vascular Malformation drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular Malformation?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Malformation therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vascular Malformation and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Atavistik
• Haihe Biopharma
• Vaderis Therapeutics
• ALMAC
• TERREMOTO
• Tectonic Therapeutics
• Protara Therapeutics
• Alnylam Pharmaceuticals
• HEMAB

Key Products

• ATV-1601
• CYH33
• Engasertib
• TER-4480
• TX-2100
• TARA-002
• ALN-6400
• HMB-003